Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Phase 1 Study of Axatilimab (SNDX-6352), a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment

Mukta Arora, MD, Madan Jagasia, MBBS, MS, MMHC, Antonio Di Stasi, MD, Michael L Meyers, MD PhD, Christine Quaranto, Aaron Schmitt, Serap Sankoh, Mohammad Issam Abu Zaid, MBBS, Geoff R Hill, MD, Daniel J. Weisdorf, MD, Bruce R. Blazar, MD, Peter Ordentlich, PhD, Stephanie J. Lee, MDMPH

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-141553

Published: 2020

Journal Articles

Cytomegalovirus Promotes Aberrant Memory CD4 T Cell Differentiation and Immune Function after Allogeneic Stem Cell Transplantation

Albert Yeh, MD, Madan Jagasia, MBBS, MS, MMHC, Kimberly Dahlman, PhD, Jonathan Michael Irish, PhD, Anupama Reddy, PhD, Sierra Barone, BS, Kate Chilson, MA, Lynn E. Onstad, ScM, Ping Zhang, MD PhD, Tae Kon Kim, MD PhD, Stephanie J. Lee, MDMPH, Geoff R Hill, MD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-134829

Published: 2020

Journal Articles

Results of a Phase III Double-Blind Study of the Addition of Tocilizumab Vs. Placebo to Cyclosporin/Methotrexate Gvhd Prophylaxis after HLA-Matched Allogeneic Stem Cell Transplantation

Glen A Kennedy, MBBS FRACP FRCPA, Siok-Keen Tey, MBBS,PhDFRACP,FRCPA, Cameron Curley, MBBS, FRACP, FRCPA, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Ashish Misra, MBBS, FRACP, Elango Subramoniapillai, MBBS, FRACP, James Morton, MBBS, FRACP, FRCPA, Simon Durrant, FRCP,FRCPath,MBBS, Andrea S Hendon, MBBS, PhD FRACP, FRCPA, John Moore, MDFRACP,FRCPA, David Ritchie, MD PhD, David Gottlieb, MBBS, MD FRACP, FRCPA, Julian Cooney, FRACP,FRCPA,MBBS,, Luke Buizen, BSc (Hons), MSc, Sanjoy K Paul, PhD, Geoff R. Hill, MD

Blood (2019) 134 (Supplement_1): 368.

https://doi.org/10.1182/blood-2019-126285

Published: 2019

Journal Articles

In Vivo Expansion of Recipient DC Leads to Deletion of Donor Alloreactive CD8 + T Cells and Is an Alternative to Post-Transplant Cyclophosphamide for the Prevention of Graft-Versus-Host Disease after BMT

Kate A Markey, MBBS, PhD, Rachel D Kuns, BSc, Daniel J Browne, BSc, Kate H Gartlan, PhD, Renee J Robb, PhD, J Paulo Martins, BSc, Andrea S Henden, MBBS, Simone A Minnie, BSc, Melody Cheong, PhD, Motoko Koyama, MD PhD, Mark J Smyth, PhD, Gabrielle T Belz, PhD, Thomas Brocker, PhD, Mariapia Degli-Esposti, PhD, Steven W. Lane, MD PhD, Geoff R Hill, MD

Blood (2017) 130 (Supplement 1): 4443.

https://doi.org/10.1182/blood.V130.Suppl_1.4443.4443

Published: 2017

Journal Articles

Recipient CD8 + DC Delete Alloreactive Donor CTL and Promote Leukemic Relapse after Allogeneic BMT

Kate A Markey, MBBS, PhD, Rachel D Kuns, BSc, Renee J Robb, PhD, Motoko Koyama, MDPhD, Kate Helen Gartlan, PhD, Andrea S Henden, MBBS, Simone A Minnie, B Sc, Kelli P A Macdonald, PhD, Thomas Brocker, PhD, Gabrielle T Belz, PhD, Steven W. Lane, MD, Geoff R Hill, MD

Blood (2015) 126 (23): 4279.

https://doi.org/10.1182/blood.V126.23.4279.4279

Published: 2015

Journal Articles

Inhibition of Telomerase with Imetelstat Is Detrimental to Leukemia Stem Cells in Acute Myeloid Leukemia (AML)

Claudia Bruedigam, Frederik Otzen Bagger, Florian H Heidel, MD, Catherine Kuhn, Solene Guignes, Axia Song, Rebecca Austin, Therese Vu, Erwin M Lee, PhD, Andrew S. Moore, MBBS, FRACP, PhD, Richard B. Lock, PhD, Lars Bullinger, MD PhD, Geoff R Hill, MD, Steven W Lane, MD PhD

Blood (2014) 124 (21): 2322.

https://doi.org/10.1182/blood.V124.21.2322.2322

Published: 2014

Journal Articles

Soluble Lymphotoxin Plays a Critical Role in Acute Graft-Versus-Host Disease

Kate A Markey, BE, Angela C Burman, PhD, Rachel D Kuns, BSc, Edward S Morris, MD, Tatjana Banovic, MD, Neil C Raffelt, BSc, Stuart D Olver, BSc, Christian R Engwerda, PhD, Heinrich Korner, PhD, Kelli P A MacDonald, PhD, Geoff R Hill, MD

Blood (2008) 112 (11): 3510.

https://doi.org/10.1182/blood.V112.11.3510.3510

Published: 2008

Journal Articles

SOCS3 Regulates Th1 Dependent Acute Graft-Versus Host Disease

Kelli P A MacDonald, PhD, Rachel D Kuns, BSc, Alistair LJ Don, BSc, Stuart D Olver, BSc, Neil C Raffelt, BSc, Kate A Markey, BE, Warren Alexander, PhD, Andrew W. Roberts, MBBS, PhD, Geoff R Hill, MD

Blood (2008) 112 (11): 3513.

https://doi.org/10.1182/blood.V112.11.3513.3513

Published: 2008

Journal Articles

Allogeneic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukaemia: Local Results of Modern Transplant Practice.

Jason P. Butler, MBBS, Glen A. Kennedy, MBBS, Geoff R. Hill, MD, James Morton, MBBS, Robyn Western, BN, Cheryl Hutchins, PhD, Simon Durrant, MBBS

Blood (2006) 108 (11): 5393.

https://doi.org/10.1182/blood.V108.11.5393.5393

Published: 2006

Journal Articles

Allogeneic Transplant Outcomes in Imatinib-Refractory Chronic Myeloid Leukaemia (CML) Are Similar to Transplant Outcomes in Imatinib-Responsive/Imatinib-Naïve CML and Appear To Be Predicted by the EBMT Risk Score.

Steven Stylian, MBBS, Eileen T. Fennelly, BN, Jason P. Butler, MBBS, James P. Morton, MBBS, Robyn Western, BN, Cheryl J. Hutchins, PhD, Geoff R. Hill, MD, Simon T. Durrant, MBBS, Glen A. Kennedy, MBBS

Blood (2006) 108 (11): 3155.

https://doi.org/10.1182/blood.V108.11.3155.3155

Published: 2006

Journal Articles

Efficacy of Soluble TNFα Inhibitor (Etanercept) for Treatment of Steroid Refractory Acute Graft Versus Host Disease (GVHD) Post Allogeneic Stem Cell Transplantation (SCT).

Glen A. Kennedy, Jason Butler, James Morton, Geoff R. Hill, MD, Robyn Western, Simon Durrant

Blood (2005) 106 (11): 1806.

https://doi.org/10.1182/blood.V106.11.1806.1806

Published: 2005

Journal Articles

Fludarabine/Melphalan Conditioning for Allogeneic Stem Cell Transplantation (SCT) in Elderly Patients with AML/MDS.

Glen A. Kennedy, Jason Butler, Simon Durrant, Geoff R. Hill, MD, Robyn Western, James Morton

Blood (2005) 106 (11): 5410.

https://doi.org/10.1182/blood.V106.11.5410.5410

Published: 2005

NARROW

Phase 1 Study of Axatilimab (SNDX-6352), a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment

Cytomegalovirus Promotes Aberrant Memory CD4 T Cell Differentiation and Immune Function after Allogeneic Stem Cell Transplantation

Results of a Phase III Double-Blind Study of the Addition of Tocilizumab Vs. Placebo to Cyclosporin/Methotrexate Gvhd Prophylaxis after HLA-Matched Allogeneic Stem Cell Transplantation

In Vivo Expansion of Recipient DC Leads to Deletion of Donor Alloreactive CD8 + T Cells and Is an Alternative to Post-Transplant Cyclophosphamide for the Prevention of Graft-Versus-Host Disease after BMT

Recipient CD8 + DC Delete Alloreactive Donor CTL and Promote Leukemic Relapse after Allogeneic BMT

Inhibition of Telomerase with Imetelstat Is Detrimental to Leukemia Stem Cells in Acute Myeloid Leukemia (AML)

Soluble Lymphotoxin Plays a Critical Role in Acute Graft-Versus-Host Disease

SOCS3 Regulates Th1 Dependent Acute Graft-Versus Host Disease

Allogeneic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukaemia: Local Results of Modern Transplant Practice.

Allogeneic Transplant Outcomes in Imatinib-Refractory Chronic Myeloid Leukaemia (CML) Are Similar to Transplant Outcomes in Imatinib-Responsive/Imatinib-Naïve CML and Appear To Be Predicted by the EBMT Risk Score.

Efficacy of Soluble TNFα Inhibitor (Etanercept) for Treatment of Steroid Refractory Acute Graft Versus Host Disease (GVHD) Post Allogeneic Stem Cell Transplantation (SCT).

Fludarabine/Melphalan Conditioning for Allogeneic Stem Cell Transplantation (SCT) in Elderly Patients with AML/MDS.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only